JPRN-jRCT2080221493
Unknown
Phase 2
The clinical study to assess the efficacy, safety and pharmacokinetics of NS-304 in patients with pulmonary arterial hypertension (PAH)
IPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd.0 sites30 target enrollmentJune 27, 2011
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- IPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd.
- Enrollment
- 30
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Idiopathic pulmonary arterial hypertension (IPAH)
- •Heritable pulmonary arterial hypertension (HPAH)
- •Drug\- and Toxin\-induced pulmonary arterial hypertension
- •PAH associated with one of the following;
- •a) connective tissue disease
- •b) congenital heart disease (At least one year should be elapsed after pulmonary shunt at the time of each baseline measurement.)
- •c) HIV infection
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A clinical Trial in patients with Vernal Keratoconjunctivitis. Clinical trial is to study efficacy, safety and tolerability of Tacrolimus Ophthalmic Suspension in comparison to Cyclosporine eye drops (reference product).CTRI/2010/091/001456Ajanta Pharma Ltd200
Completed
Not Applicable
A Clinical Study to Evaluate the Efficacy, Safety and Consumer Perception of a Moisturizing Productsensitive skinJPRN-UMIN000047956ION CORPORATIO35
Completed
Phase 2
se of Roselle in Bronchial asthma and MalnutritioHealth Condition 1: J454- Moderate persistent asthmaCTRI/2020/08/027013DXN Manufacturing India Pvt Ltd12
Completed
Phase 2
se of Noni juice in Bronchial asthma and malnutritioHealth Condition 1: J454- Moderate persistent asthmaCTRI/2020/08/027012DXN Manufacturing India Pvt Ltd12
Completed
Phase 4
effect of Kanak taila in reducing wrinkles and promoting skin brightening.CTRI/2021/09/036560Ms Ozone Pharmaceuticals Ltd50